(ARGX) argenx - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 45.321m USD | Total Return: 26.5% in 12m

Stock Biologics, Treatments, Autoimmune
Total Rating 53
Safety 67
Buy Signal 0.28
Biotechnology +0.2
Biotechnology +1.0
Market Cap: 45,321m
Avg Trading Vol: 253M USD
ATR: 2.79%
Peers RS (IBD): 25.8
Risk 5d forecast
Volatility38.0%
Rel. Tail Risk-16.1%
Reward TTM
Sharpe Ratio0.67
Alpha16.25
Character TTM
Beta0.244
Beta Downside1.140
Drawdowns 3y
Max DD38.20%
CAGR/Max DD0.68
EPS (Earnings per Share) EPS (Earnings per Share) of ARGX over the last years for every Quarter: "2021-03": -0.67, "2021-06": 1.98, "2021-09": -4.1, "2021-12": -5.06, "2022-03": -4.36, "2022-06": -3.8, "2022-09": -4.26, "2022-12": -0.7, "2023-03": -0.71, "2023-06": -1.69, "2023-09": -1.25, "2023-12": -1.68, "2024-03": -1.04, "2024-06": 0.45, "2024-09": 1.39, "2024-12": 0.7125, "2025-03": 2.2732, "2025-06": 3.2572, "2025-09": 5.18, "2025-12": 6.7945, "2026-03": 0,
EPS CAGR: 69.25%
EPS Trend: 84.9%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of ARGX over the last years for every Quarter: 2021-03: 158.155, 2021-06: 420.444, 2021-09: 0.857, 2021-12: 26.039, 2022-03: 23.412, 2022-06: 111.355, 2022-09: 137.981, 2022-12: 302.907, 2023-03: -257.981, 2023-06: 468.203, 2023-09: 329.789, 2023-12: 757.679, 2024-03: 401.001, 2024-06: 901.941, 2024-09: 573.236, 2024-12: 1346.264, 2025-03: 790.683, 2025-06: 947.961, 2025-09: 1126.961, 2025-12: 2406.376697, 2026-03: null,
Rev. CAGR: 243.96%
Rev. Trend: 47.0%
Last SUE: 3.68
Qual. Beats: 3
Description: ARGX argenx

argenx SE is a commercial-stage biopharmaceutical company focused on developing treatments for autoimmune diseases. Its primary products, VYGART and VYGART HYTRULO, address conditions such as generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). The biopharmaceutical sector is characterized by high research and development costs and a lengthy drug approval process.

The companys pipeline includes efgartigimod for various autoimmune indications like thyroid eye diseases and lupus nephropathy, and empasiprubart for conditions such as multifocal motor neuropathy and dermatomyositis. argenx also has early-stage programs, including ARGX-119 for neurological disorders and ARGX-109 for inflammation. Biopharmaceutical companies often rely on strategic collaborations to share development risks and expand market reach, as evidenced by argenxs numerous partnerships.

Further research on platforms like ValueRay can provide detailed financial metrics and competitive analysis for ARGX.

Headlines to Watch Out For
  • VYGART sales growth drives revenue expansion
  • Pipeline drug approvals impact future revenue streams
  • Clinical trial failures increase development costs
  • Competition from new autoimmune therapies threatens market share
Piotroski VR‑10 (Strict) 6.0
Net Income: 1.63b TTM > 0 and > 6% of Revenue
FCF/TA: 0.10 > 0.02 and ΔFCF/TA 11.03 > 1.0
NWC/Revenue: 105.8% < 20% (prev 130.7%; Δ -24.92% < -1%)
CFO/TA 0.10 > 3% & CFO 845.6m > Net Income 1.63b
Net Debt (-3.41b) to EBITDA (1.51b): -2.26 < 3
Current Ratio: 5.23 > 1.5 & < 3
Outstanding Shares: last quarter (66.2m) vs 12m ago 0.66% < -2%
Gross Margin: 89.39% > 18% (prev 0.90%; Δ 8.85k% > 0.5%)
Asset Turnover: 70.84% > 50% (prev 51.95%; Δ 18.88% > 0%)
Interest Coverage Ratio: 98.73 > 6 (EBITDA TTM 1.51b / Interest Expense TTM 5.07m)
Altman Z'' 4.41
A: 0.64 (Total Current Assets 6.90b - Total Current Liabilities 1.32b) / Total Assets 8.68b
B: -0.03 (Retained Earnings -279.8m / Total Assets 8.68b)
C: 0.07 (EBIT TTM 500.6m / Avg Total Assets 7.44b)
D: -0.15 (Book Value of Equity -198.8m / Total Liabilities 1.36b)
Altman-Z'' Score: 4.41 = AA
Beneish M -2.40
DSRI: 1.11 (Receivables 1.66b/909.1m, Revenue 5.27b/3.22b)
GMI: 1.00 (GM 89.39% / 89.77%)
AQI: 0.97 (AQ_t 0.20 / AQ_t-1 0.21)
SGI: 1.64 (Revenue 5.27b / 3.22b)
TATA: 0.09 (NI 1.63b - CFO 845.6m) / TA 8.68b)
Beneish M-Score: -2.40 (Cap -4..+1) = BBB
What is the price of ARGX shares? As of April 05, 2026, the stock is trading at USD 730.25 with a total of 368,477 shares traded.
Over the past week, the price has changed by +7.96%, over one month by -0.31%, over three months by -6.80% and over the past year by +26.50%.
Is ARGX a buy, sell or hold? argenx has received a consensus analysts rating of 4.59. Therefore, it is recommended to buy ARGX.
  • StrongBuy: 14
  • Buy: 7
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the ARGX price?
Wallstreet Target Price 1021.2 39.8%
Analysts Target Price 1021.2 39.8%
ARGX Fundamental Data Overview as of 02 April 2026
P/E Trailing = 37.3148
P/E Forward = 27.7008
P/S = 10.6979
P/B = 6.1888
P/EG = 1.176
Revenue TTM = 5.27b USD
EBIT TTM = 500.6m USD
EBITDA TTM = 1.51b USD
Long Term Debt = 47.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 10.8m USD (from shortTermDebt, last quarter)
Debt = 83.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.41b USD (from netDebt column, last quarter)
Enterprise Value = 40.96b USD (45.32b + Debt 83.5m - CCE 4.44b)
Interest Coverage Ratio = 98.73 (Ebit TTM 500.6m / Interest Expense TTM 5.07m)
EV/FCF = 48.80x (Enterprise Value 40.96b / FCF TTM 839.5m)
FCF Yield = 2.05% (FCF TTM 839.5m / Enterprise Value 40.96b)
FCF Margin = 15.92% (FCF TTM 839.5m / Revenue TTM 5.27b)
Net Margin = 30.99% (Net Income TTM 1.63b / Revenue TTM 5.27b)
Gross Margin = 89.39% ((Revenue TTM 5.27b - Cost of Revenue TTM 559.4m) / Revenue TTM)
Gross Margin QoQ = 89.26% (prev 90.29%)
Tobins Q-Ratio = 4.72 (Enterprise Value 40.96b / Total Assets 8.68b)
Interest Expense / Debt = 2.18% (Interest Expense 1.82m / Debt 83.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = 395.5m (EBIT 500.6m * (1 - 21.00%))
Current Ratio = 5.23 (Total Current Assets 6.90b / Total Current Liabilities 1.32b)
Debt / Equity = 0.01 (Debt 83.5m / totalStockholderEquity, last quarter 7.32b)
Debt / EBITDA = -2.26 (Net Debt -3.41b / EBITDA 1.51b)
Debt / FCF = -4.06 (Net Debt -3.41b / FCF TTM 839.5m)
Total Stockholder Equity = 5.79b (last 4 quarters mean from totalStockholderEquity)
RoA = 21.95% (Net Income 1.63b / Total Assets 8.68b)
RoE = 28.20% (Net Income TTM 1.63b / Total Stockholder Equity 5.79b)
RoCE = 8.57% (EBIT 500.6m / Capital Employed (Equity 5.79b + L.T.Debt 47.2m))
RoIC = 6.27% (NOPAT 395.5m / Invested Capital 6.31b)
WACC = 6.83% (E(45.32b)/V(45.40b) * Re(6.84%) + D(83.5m)/V(45.40b) * Rd(2.18%) * (1-Tc(0.21)))
Discount Rate = 6.84% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 33.33 | Cagr: 6.58%
[DCF] Terminal Value 76.40% ; FCFF base≈839.5m ; Y1≈551.2m ; Y5≈252.1m
[DCF] Fair Price = 157.6 (EV 6.38b - Net Debt -3.41b = Equity 9.78b / Shares 62.1m; r=6.83% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 84.92 | EPS CAGR: 69.25% | SUE: -4.0 | # QB: 0
Revenue Correlation: 47.02 | Revenue CAGR: 244.0% | SUE: 3.68 | # QB: 3
EPS next Quarter (2026-06-30): EPS=4.90 | Chg7d=-0.093 | Chg30d=-1.565 | Revisions Net=-6 | Analysts=11
EPS current Year (2026-12-31): EPS=21.56 | Chg7d=-0.076 | Chg30d=-4.515 | Revisions Net=-9 | Growth EPS=+30.0% | Growth Revenue=+42.1%
EPS next Year (2027-12-31): EPS=28.59 | Chg7d=+0.194 | Chg30d=-3.172 | Revisions Net=-9 | Growth EPS=+32.6% | Growth Revenue=+19.3%
[Analyst] Revisions Ratio: -0.75 (1 Up / 7 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.2% (Discount Rate 7.9% - Earnings Yield 2.7%)
[Growth] Growth Spread = +42.1% (Analyst 47.4% - Implied 5.2%)
External Resources
Dataroma Stockcircle